Sibel Yilmaz is an of counsel with Covington & Burling, based in the firm’s Brussels office. She has particular expertise in the life sciences sector and has been involved in some of the industry’s most high profile matters in recent years, including representing Novartis on its $30 billion acquisition of GSK’s oncology business, advising Takeda on its sale of certain respiratory products to AstraZeneca and representing clients in several investigations relating to alleged excessive prices and other non-competitive practices in the life science sector. Sibel is ranked among the world’s top antitrust practitioners by Global Competition Review, who included her in their most recent 40 Under 40 survey, as well as Chambers Global. She is described as "a brilliant and promising lawyer, who is highly recommended for complex merger work” and “an exceptional talent”, "absolutely a tip for the top."Sibel received her LL.M. in Law and Economics from the University of Rotterdam and Master of Law from Stockholm University and is admitted to practice in Belgium and Sweden.
77
What does the new EU Foreign Subsidies Regulation (FSR) mean for companies doing business in the EU?* The EU Foreign Subsidies Regulation (FSR) adopted in December 2022 creates a new instrument to prevent foreign subsidies from distorting the European Union (EU) internal market. It aims to (...)
279
Regulation (EU) 2022/2560 of the European Parliament and of the Council of 14 December 2022 on foreign subsidies distorting the internal market (FSR) entered into force on 12 January 2023 and will start to apply as of 12 July 2023. The FSR creates a brand new instrument to fill a regulatory (...)
